Published 2 December 2008, doi:10.1136/bmj.a2591
Cite this as: BMJ 2008;337:a2591

Analysis

What can we learn from drug marketing efficiency?

¹ University of Colorado Health Sciences Center, Academic Office 1, 12631 E 17th Avenue, Suite 7102, Aurora, CO 80045 USA

The time it takes new drugs to penetrate the market is shrinking. David Kao suggests how drug companies’ techniques could be used to improve safety surveillance systems

The first 150 words of the full text of this article appear below.

Institutions responsible for monitoring drug safety have been criticised widely after the withdrawal of drugs such as rofecoxib because of safety concerns. An estimated 20 million patients received prescriptions for rofecoxib over five years before the drug was withdrawn, and events attributable to rofecoxib may number in tens to hundreds of thousands.¹ Regulatory bodies such as the US Food and Drug Administration have simultaneously been under pressure to reduce drug approval times to ensure timely availability of new drugs. However, concerns have been expressed that deadlines for approving drugs have reduced the focus on safety.^{2 3 4}

New efficiencies in drug marketing exacerbate the problem because rapid adoption of new drugs can quickly expose large numbers of patients to unknown risks. Here, I review trends in drug approval times in the United States, the mechanism by which this has been achieved, and concerns raised by this approach. I then discuss an example . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Commentary: The balance between marketing and safety

Keith Beard
BMJ 2008 337: a2996. [Extract] [Full Text]

What have we learnt from Vioxx?

Harlan M Krumholz, Joseph S Ross, Amos H Presler, and David S Egilman
BMJ 2007 334: 120-123. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Beard, K. (2008). Commentary: The balance between marketing and safety. BMJ 337: a2996-a2996 [Full text]  

Rapid Responses:

Read all Rapid Responses

Drug Marketing Efficiency

Manthan D Janodia, et al.
bmj.com, 3 Dec 2008 [Full text]

marketing is harmful

David Egilman
bmj.com, 5 Jan 2009 [Full text]

The law lags behind the science

Andre R Menache
bmj.com, 18 Jan 2009 [Full text]

EU-ADR: a European multifaceted approach to improving postmarketing surveillance of drugs

Miriam C Sturkenboom, et al.
bmj.com, 26 Feb 2009 [Full text]

Online poll

Find out more on doc2doc >>